Drug intelligence / Profile preview

EnvPro

Development stage: Phase 1
Lead developer: National Institute of Allergy and Infectious Diseases
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular (inferred From Standard Administration Route For Protein Vaccines; Not Explicitly Stated)

Overview

EnvPro is a recombinant purified HIV envelope vaccine developed by the National Institute of Allergy & Infectious Diseases (NIAID). It is classified as an immunostimulant and functions as a vaccine designed to stimulate the immune system against HIV. In clinical studies, it was administered with alum, an adjuvant used to enhance immune response. The primary indication for EnvPro is prevention of HIV infection in healthy adults. Its mechanism involves stimulating the immune system to recognize and respond to HIV envelope proteins[1].

Brand names: EnvPro
Other names: EnvPro

Targets

gp41 (Human immunodeficiency virus type 1 glycoprotein 41)

Beyond the preview

Go deeper on EnvPro.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EnvPro.

Explore the full profile